Tabor Asset Management LP Buys Shares of 32,000 LENSAR, Inc. (NASDAQ:LNSR)

Tabor Asset Management LP purchased a new stake in LENSAR, Inc. (NASDAQ:LNSR - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund purchased 32,000 shares of the company's stock, valued at approximately $452,000. Tabor Asset Management LP owned 0.27% of LENSAR as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of LNSR. Geode Capital Management LLC boosted its holdings in shares of LENSAR by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 106,058 shares of the company's stock valued at $948,000 after buying an additional 5,627 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of LENSAR by 13.3% in the 4th quarter. Renaissance Technologies LLC now owns 348,891 shares of the company's stock valued at $3,119,000 after buying an additional 40,946 shares during the period. Huntleigh Advisors Inc. acquired a new position in shares of LENSAR in the 1st quarter valued at about $1,069,000. Finally, Draper Asset Management LLC acquired a new position in shares of LENSAR in the 1st quarter valued at about $565,000. 40.15% of the stock is owned by institutional investors and hedge funds.

LENSAR Stock Performance

Shares of NASDAQ LNSR traded up $0.10 during midday trading on Friday, hitting $13.03. The company's stock had a trading volume of 6,693 shares, compared to its average volume of 139,278. LENSAR, Inc. has a 1-year low of $3.50 and a 1-year high of $17.31. The firm's fifty day moving average price is $13.10 and its 200-day moving average price is $12.62. The firm has a market cap of $153.56 million, a P/E ratio of -2.69 and a beta of 0.50.

LENSAR (NASDAQ:LNSR - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($2.16). The firm had revenue of $11.53 million for the quarter, compared to analyst estimates of $13.40 million. LENSAR had a negative net margin of 99.17% and a negative return on equity of 737.30%.

LENSAR Company Profile

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.